Orforglipron vs Tirzepatide
Last updated
Compare the ingredients, then check the specific brand, formulation, and dose. Approved uses and prices vary by product.
Orforglipron vs Tirzepatide: lowest prices now



Tirzepatide: lowest compounded on a monthly plan, not FDA-approved
$69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before
| Compare | Orforglipron | Tirzepatide |
|---|---|---|
| What it is for | FDA-approved for
| FDA-approved for
|
| Brands | Foundayo Small-molecule GLP-1 | Mounjaro, Zepbound GIP/GLP-1 |
| Route & frequency | Oral tablet (any time of day, no food or water restriction) Once daily | Subcutaneous injection Once weekly |
| FDA shortage report | National reporting does not confirm stock at your pharmacy. Coverage & source records | National reporting does not confirm stock at your pharmacy. Coverage & source records |
Direct comparative evidence
No direct comparative trial is included for these ingredients in our reviewed catalog. The separate trial results below do not establish which works better.
What the quoted price covers
Lowest tracked quotes for FDA-approved products, selected separately for each price basis. Entry prices may refer to different brands or formulations. Supply periods, eligibility, refill deadlines, and additional fees can change what you pay.
| Compare | Orforglipron | Tirzepatide |
|---|---|---|
| Advertised entry price | $149/30 days (pharmacy.amazon.com/FOUNDAYO-0-8-MG-TABLET-Bottle-30-Tablet/dp/B0GVPY57CT) Foundayo via Amazon Pharmacy Amazon Pharmacy without insurance, 0.8 mg; includes the manufacturer coupon if eligible (list price $648.90); prescription required 30-day supply (pharmacy.amazon.com) $149 per 30 days at this quoted rate Offer through Checked on pharmacy.amazon.com Price conditionswithout insurance, 0.8 mg; includes the manufacturer coupon if eligible (list price $648.90); prescription required Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product. 30-day supply | $299/28 days (pharmacy.amazon.com/ZEPBOUND-KWIKPEN-2-5-MG-DOSE-PEN-INJ/dp/B0GP27N9T3) Zepbound KwikPen via Amazon Pharmacy Amazon Pharmacy without insurance, 2.5 mg; includes the manufacturer coupon if eligible (list price $498.98); prescription required 28-day supply (pharmacy.amazon.com) ≈ $320.36 per 30 days at this quoted rate Offer through Checked on pharmacy.amazon.com Price conditionswithout insurance, 2.5 mg; includes the manufacturer coupon if eligible (list price $498.98); prescription required The 7.5 mg KwikPen is also $449. Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product. 28-day supply |
| At the named trial dose | $299/30 days (pharmacy.amazon.com/Eli-Lilly-FOUNDAYO-17-2-MG-TABLET-Bottle-30-Tablet/dp/B0GVPWWC4K) Foundayo via Amazon Pharmacy At 17.2 mg Amazon Pharmacy without insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Foundayo savings page states (otherwise Lilly's regular $349); 17.2 mg; includes the manufacturer coupon if eligible (list price $648.90) 30-day supply (pharmacy.amazon.com) $299 per 30 days at this quoted rate Offer through Checked on pharmacy.amazon.com Price conditionswithout insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Foundayo savings page states (otherwise Lilly's regular $349); 17.2 mg; includes the manufacturer coupon if eligible (list price $648.90) Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product. 30-day supply | $449/28 days (pharmacy.amazon.com/ZEPBOUND-KWIKPEN-15-MG-DOSE-PEN-INJ/dp/B0GP1V2X9V) Zepbound KwikPen via Amazon Pharmacy At 15 mg Amazon Pharmacy without insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Zepbound savings page states (otherwise Lilly's regular $699); 15 mg; includes the manufacturer coupon if eligible (list price $699) 28-day supply (pharmacy.amazon.com) ≈ $481.07 per 30 days at this quoted rate Offer through Checked on pharmacy.amazon.com Price conditionswithout insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Zepbound savings page states (otherwise Lilly's regular $699); 15 mg; includes the manufacturer coupon if eligible (list price $699) The 7.5 mg KwikPen is also $449. Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product. 28-day supply |
| Every offer | All 51 offersAll 51 orforglipron offers | All 885 offersAll 885 tirzepatide offers |
USD self-pay, not insurance or pharmacy acquisition cost. A trial dose is not a personal dosing recommendation. Compounded offers are shown separately in the offer browser and are not FDA-approved.
Trial outcomes in context
Each result belongs to its own trial, population, dose, and analysis. Weight loss, HbA1c change, and adverse events may come from different studies even within one ingredient. These are study averages, not predictions of your result.
| Compare | Orforglipron | Tirzepatide |
|---|---|---|
| Weight change | −11.2% (nejm.org/doi/abs/10.1056/NEJMoa2511774) (-11.2% at 72 wks · ATTAIN-1 · 17.2 mg daily (Foundayo; the label's equivalent of ATTAIN-1's 36 mg dose)) -11.2% at 72 wks ATTAIN-1 (nejm.org)17.2 mg daily (Foundayo; the label's equivalent of ATTAIN-1's 36 mg dose) Accounts for treatment discontinuation Study contextThe first oral small-molecule GLP-1 pill for weight loss (Foundayo, FDA-approved April 2026): pill convenience with injectable-class efficacy. -11.2% is the primary (treatment-regimen) endpoint; the efficacy estimand was -12.4%. | −20.9% (nejm.org/doi/full/10.1056/NEJMoa2206038) (-20.9% at 72 wks · SURMOUNT-1 · 15 mg weekly (Zepbound)) -20.9% at 72 wks SURMOUNT-1 (nejm.org)15 mg weekly (Zepbound) Accounts for treatment discontinuation Study contextSURMOUNT-1 studied adults with obesity or overweight without diabetes. This result belongs to the 15 mg arm and the treatment-regimen analysis; other doses and analyses have different results. |
| HbA1c change (percentage points) | −1.5 pp (investor.lilly.com/node/52521) (-1.5 percentage points at 40 wks (36 mg, ACHIEVE-1) · ACHIEVE-1 · HbA1c change in percentage points) -1.5 percentage points at 40 wks (36 mg, ACHIEVE-1) ACHIEVE-1 (investor.lilly.com) | −2.3 pp (investor.lilly.com/news-releases/news-release-details/lillys-surpass-2-results-published-new-england-journal-medicine) (-2.3% at 40 wks · SURPASS-2 · HbA1c change in percentage points) -2.3 percentage points at 40 wks SURPASS-2 (investor.lilly.com) |
| Adverse events | Stopped treatment for adverse events 10.3% (nejm.org/doi/abs/10.1056/NEJMoa2511774) (10.3% vs 2.7% placebo (36 mg) · ATTAIN-1 (36 mg, 72 wks, obesity))Reported nausea 33.7% (nejm.org/doi/abs/10.1056/NEJMoa2511774) (Nausea in the drug arm · ATTAIN-1 (36 mg, 72 wks, obesity))ATTAIN-1 (36 mg, 72 wks, obesity) | Stopped treatment for adverse events 6.2% (nejm.org/doi/full/10.1056/NEJMoa2206038) (6.2% vs 2.6% placebo (15 mg) · SURMOUNT-1 (15 mg, 72 wks, obesity))Reported nausea 31% (nejm.org/doi/full/10.1056/NEJMoa2206038) (Nausea in the drug arm · SURMOUNT-1 (15 mg, 72 wks, obesity))SURMOUNT-1 (15 mg, 72 wks, obesity) |
Timing, generics and coverage
Read from each FDA label, FDA's Orange Book and CMS's Part D files, and updated when they change.
| Brand | Soonest top dose | Half-life | Generic approved? | Patent on the medicine to | On Medicare Part D, 2025 |
|---|---|---|---|---|---|
| Mounjaro | 15 mg from week 21 | about 5 days | No | Jun 14, 2039 | 1,592,517 |
| Zepbound | 15 mg from week 21 | about 5-6 days | No | May 13, 2036 | 160,298 |
| Foundayo | 17.2 mg from day 151 | about 29 to 49 hours | No | Sep 26, 2037 | None listed |
How long each takes · Generics and patents · Who covers what
Approved uses & full records
Orforglipron
Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.
53 registered ingredient studies (clinicaltrials.gov/search). Count checked . Research activity, not a measure of evidence quality.
Open full recordTirzepatide
Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.
317 registered ingredient studies (clinicaltrials.gov/search). Count checked . Research activity, not a measure of evidence quality.
Open full recordCommon questions
Is Orforglipron or Tirzepatide better for weight loss?
No trial on our list compared them directly. In separate trials: Orforglipron -11.2% at 72 wks in ATTAIN-1 (17.2 mg daily (Foundayo; the label's equivalent of ATTAIN-1's 36 mg dose)) (nejm.org); Tirzepatide -20.9% at 72 wks in SURMOUNT-1 (15 mg weekly (Zepbound)) (nejm.org). Separate trials enrolled different people for different lengths of time, so these figures cannot rank them.
Is Orforglipron or Tirzepatide safer?
We know of no trial set up to answer that. Stopping because of side effects, each in its own trial and not a head-to-head figure: Orforglipron 10.3% vs 2.7% placebo (36 mg) (ATTAIN-1 (36 mg, 72 wks, obesity)) (nejm.org); Tirzepatide 6.2% vs 2.6% placebo (15 mg) (SURMOUNT-1 (15 mg, 72 wks, obesity)) (nejm.org). Each FDA label lists its own warnings, and which ones matter depends on your health.
What Tirzepatide dose is equivalent to Orforglipron?
No FDA label sets a dose of Orforglipron that equals a dose of Tirzepatide, and we know of no trial that defines one. Switching is a prescriber's decision, and each label sets its own starting dose and steps.
Which costs less: Orforglipron or Tirzepatide?
Compare the named products and price conditions below. A tracked entry quote can be a different brand or formulation from the product studied in a trial. A trial-dose quote applies only to the named product and dose; neither figure is an estimate of your whole treatment cost or an insurance quote.
Do these trial results tell me which medication is best?
Direct trials compare the treatments, doses, and participants they studied. Results from separate trials differ in population, duration, dose, and analysis, so their percentages do not establish a treatment ranking. Discuss your medical history and the specific product label with a licensed clinician.
Does FDA shortage status mean my pharmacy has stock?
No. FDA shortage records describe national supply reports and covered presentations, not inventory at an individual pharmacy. Unknown status means the data cannot establish a current assessment. Confirm local stock with your pharmacy.
What changed for Orforglipron and Tirzepatide
- PriceProtocol MD: Compounded tirzepatide via Protocol MD now $299/mo (was $319/mo) (read on protocolmd.com)
- PriceCorrected: Telezen MD, Compounded tirzepatide via Telezen MD, $228/mo on its own page (we had from $159/mo) (read on telezenmd.com)
- PriceCorrected: Ascend Vitality, Compounded tirzepatide via Ascend Vitality, $199/mo on its own page (we had from $119/mo) (read on av-life.com)
- PriceNexLife: Microdose tirzepatide via NexLife now $129/mo (was $159/mo) (read on nexlife.com)
- PriceRow Telehealth: Compounded tirzepatide via Row Telehealth now $249/mo (was from $249/mo) (read on rowtelehealth.com)
- PriceRow Telehealth: Compounded tirzepatide dissolving tablets (ODT) via Row Telehealth now $229/mo (was from $229/mo) (read on rowtelehealth.com)
Written from each source's own record as it changes. Every change on GLPcompare
Automated feed checks do not constitute a clinical or editorial review. Sources & methodology